In our study, we demonstrated that PD-L1 was significantly declined in unresponsive tumors compared with those that were positive in anti-PD1 responses in HCC patients, which is consistent with a previous study (7). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.